|
HU228769B1
(en)
*
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US7629360B2
(en)
*
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
|
NZ526683A
(en)
|
2000-11-30 |
2008-03-28 |
Childrens Medical Center |
Synthesis of 4-amino-thalidomide and its enantiomers that are suitable for inhibiting angiogenesis
|
|
US7091353B2
(en)
*
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
CA2498319A1
(en)
*
|
2002-09-09 |
2004-03-18 |
Nautilus Biotech |
Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
US6887855B2
(en)
|
2003-03-17 |
2005-05-03 |
Pharmion Corporation |
Forms of 5-azacytidine
|
|
US6943249B2
(en)
|
2003-03-17 |
2005-09-13 |
Ash Stevens, Inc. |
Methods for isolating crystalline Form I of 5-azacytidine
|
|
US7825136B2
(en)
*
|
2003-07-10 |
2010-11-02 |
Vertex Pharmaceuticals Incorporated |
Potentiators of antibacterial activity
|
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
|
NZ548049A
(en)
*
|
2003-12-02 |
2009-01-31 |
Celgene Corp |
Methods and compositions for the treatment and management of hemoglobinopathy and anemia
|
|
US20050143344A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
|
MXPA06010699A
(es)
*
|
2004-03-22 |
2006-12-15 |
Celgene Corp |
Metodos de usos y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades o alteraciones de la piel.
|
|
US20050222209A1
(en)
*
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
|
CN1968695A
(zh)
*
|
2004-04-14 |
2007-05-23 |
细胞基因公司 |
含有用于治疗和控制骨髓发育不良综合征的免疫调节化合物的组合物和使用方法
|
|
JP2007533761A
(ja)
*
|
2004-04-23 |
2007-11-22 |
セルジーン・コーポレーション |
肺高血圧症を治療し管理するための、免疫調節性化合物の使用方法及び免疫調節性化合物を含む組成物
|
|
WO2005112928A1
(en)
*
|
2004-05-05 |
2005-12-01 |
Celgene Corporation |
Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
|
|
ES2437592T3
(es)
*
|
2004-09-03 |
2014-01-13 |
Celgene Corporation |
Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
|
|
CA2588597A1
(en)
*
|
2004-11-23 |
2006-06-01 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
|
|
JP5366544B2
(ja)
|
2005-06-30 |
2013-12-11 |
セルジーン コーポレイション |
４−アミノ−２−（２，６−ジオキソピペリジン−３−イル）イソインドリン−１，３−ジオン化合物を調製するための方法
|
|
US20070066512A1
(en)
*
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
|
JP5436860B2
(ja)
*
|
2005-11-09 |
2014-03-05 |
オニキス セラピューティクス， インク． |
酵素阻害のための化合物
|
|
AU2006332680A1
(en)
*
|
2005-12-29 |
2007-07-12 |
Anthrogenesis Corporation |
Improved composition for collecting and preserving placental stem cells and methods of using the composition
|
|
US20080064876A1
(en)
*
|
2006-05-16 |
2008-03-13 |
Muller George W |
Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
|
NZ573759A
(en)
|
2006-06-19 |
2012-03-30 |
Proteolix Inc |
Peptide epoxyketones for proteasome inhibition
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
LT2420498T
(lt)
|
2006-09-26 |
2017-10-25 |
Celgene Corporation |
5-pakeistieji chinazolinono dariniai, kaip priešvėžiniai agentai
|
|
EP2081561A2
(en)
*
|
2006-10-19 |
2009-07-29 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases
|
|
ES2523925T3
(es)
|
2007-09-26 |
2014-12-02 |
Celgene Corporation |
Derivados de quinazolinona sustituidos en posición 6, 7 u 8 y composiciones que los contienen y métodos de uso de los mismos
|
|
EA018973B1
(ru)
|
2007-10-04 |
2013-12-30 |
Оникс Терапьютикс, Инк. |
Кристаллические пептидные кето-эпоксидные ингибиторы протеаз и синтез кето-эпоксидов аминокислот
|
|
CA2742252A1
(en)
*
|
2007-11-01 |
2009-05-07 |
Celgene Corporation |
Cytidine analogs for treatment of myelodysplastic syndromes
|
|
WO2009097120A1
(en)
*
|
2008-01-29 |
2009-08-06 |
Celgene Corporation |
Methods using immunomodulatory compounds for modulating level of cd59
|
|
US20090298882A1
(en)
*
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
|
HUE055911T2
(hu)
|
2008-05-15 |
2021-12-28 |
Celgene Corp |
Citidin-analógokat tartalmazó orális készítmények, és eljárások azok alkalmazására
|
|
BRPI0919668A2
(pt)
|
2008-10-21 |
2018-05-29 |
Onyx Therapeutics, Inc. |
terapia de combinação com epóxi-cetonas de peptídeo
|
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
|
EP2358697B1
(en)
|
2008-10-29 |
2015-10-21 |
Celgene Corporation |
Isoindoline compounds for use in the treatment of cancer.
|
|
WO2010054833A1
(de)
*
|
2008-11-14 |
2010-05-20 |
Ratiopharm Gmbh |
Intermediate und orale darreichungsformen enthaltend lenalidomid
|
|
EP2367553B1
(en)
|
2008-12-05 |
2017-05-03 |
Novo Nordisk A/S |
Combination therapy to enhance nk cell mediated cytotoxicity
|
|
US20120053159A1
(en)
|
2009-02-11 |
2012-03-01 |
Muller George W |
Isotopologues of lenalidomide
|
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
|
AU2010249615B2
(en)
|
2009-05-19 |
2013-07-18 |
Celgene Corporation |
Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
|
|
EP2436387B1
(en)
|
2009-05-25 |
2018-07-25 |
Celgene Corporation |
Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
|
|
CN101696205B
(zh)
|
2009-11-02 |
2011-10-19 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
|
|
EP2498793B1
(en)
|
2009-11-13 |
2019-07-10 |
Onyx Therapeutics, Inc. |
Oprozomib for use in metastasis suppression
|
|
RU2012131164A
(ru)
|
2009-12-22 |
2014-01-27 |
Селджин Корпорейшн |
(метилсульфонил)этил-бензол-изоиндолиновые производные и их терапевтическое применение
|
|
SG10201501062SA
(en)
|
2010-02-11 |
2015-04-29 |
Celgene Corp |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
|
PH12012501719A1
(en)
|
2010-03-01 |
2012-11-12 |
Onyx Therapeutics Inc |
Compounds for immunoproteasome inhibition
|
|
US8697646B2
(en)
|
2010-04-07 |
2014-04-15 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
|
IL250234B2
(en)
|
2010-04-07 |
2023-10-01 |
Anthrogenesis Llc |
Angiogenesis using placental stem cells
|
|
US20110301199A1
(en)
*
|
2010-06-07 |
2011-12-08 |
Telik, Inc. |
Compositions and methods for treating myelodysplastic syndrome
|
|
US8759303B2
(en)
|
2010-06-07 |
2014-06-24 |
Telik, Inc. |
Compositions and methods for treating myelodysplastic syndrome
|
|
ES2664872T3
(es)
|
2010-06-18 |
2018-04-23 |
Taiho Pharmaceutical Co., Ltd |
Moduladores PRPK-TPRKB y sus usos
|
|
AU2011352036A1
(en)
|
2010-12-31 |
2013-07-18 |
Anthrogenesis Corporation |
Enhancement of placental stem cell potency using modulatory RNA molecules
|
|
CN103402980B
(zh)
|
2011-01-10 |
2016-06-29 |
细胞基因公司 |
作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物
|
|
JP2014503597A
(ja)
|
2011-01-31 |
2014-02-13 |
セルジーン コーポレイション |
シチジンアナログの医薬組成物及びその使用方法
|
|
RS56770B1
(sr)
|
2011-03-11 |
2018-04-30 |
Celgene Corp |
Čvrste forme 3-(5-amino-2-metil-4-okso-4h-hinazolin-3-il)-piperidin-2,6-diona i njihove farmaceutske smeše i upotrebe
|
|
AU2012236655B2
(en)
|
2011-03-28 |
2016-09-22 |
Deuterx, Llc, |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
|
JP6289361B2
(ja)
|
2011-03-31 |
2018-03-07 |
セルジーン インターナショナル サルル |
５−アザシチジンの合成
|
|
EP3096142A3
(en)
|
2011-04-29 |
2017-03-08 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
|
CN104220081A
(zh)
|
2011-06-01 |
2014-12-17 |
人类起源公司 |
利用胎盘干细胞治疗疼痛
|
|
WO2012177678A2
(en)
|
2011-06-22 |
2012-12-27 |
Celgene Corporation |
Isotopologues of pomalidomide
|
|
WO2013022872A1
(en)
|
2011-08-10 |
2013-02-14 |
Celgene Corporation |
Gene methylation biomarkers and methods of use thereof
|
|
EP2765993B1
(en)
|
2011-09-14 |
2020-05-20 |
Amgen (Europe) GmbH |
Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2, 3-dihydro-1h-isoindol-4-yl}-amide
|
|
HUE050327T2
(hu)
|
2011-12-27 |
2020-11-30 |
Amgen Europe Gmbh |
Készítmények (+)-2-[1-(3-etoxi-4-metoxifenil)-2-metánszulfonil-etil]-4-acetilaminoizoindolin-1,3-dion tartalommal
|
|
WO2013126394A1
(en)
|
2012-02-21 |
2013-08-29 |
Celgene Corporation |
Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
|
CA2877736C
(en)
|
2012-06-29 |
2021-12-07 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
|
US9309283B2
(en)
|
2012-07-09 |
2016-04-12 |
Onyx Therapeutics, Inc. |
Prodrugs of peptide epoxy ketone protease inhibitors
|
|
TR201904785T4
(tr)
|
2012-08-09 |
2019-05-21 |
Celgene Corp |
(S)-3-(4-((4-MORFOLINOMETİL)BENZİL)OKSİ)-1-OKSOİZOİNDOLİN-2-il)PİPERİDİN-2,6-DİON HİDROKLORİDİN BİR KATI FORMU.
|
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
|
US10077426B2
(en)
*
|
2012-12-06 |
2018-09-18 |
Enlivex Therapeutics Ltd |
Therapeutic apoptotic cell preparations, method for producing same and uses thereof
|
|
CA2935495C
(en)
|
2013-01-14 |
2021-04-20 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
|
US9695145B2
(en)
|
2013-01-22 |
2017-07-04 |
Celgene Corporation |
Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
|
|
EP2764866A1
(en)
|
2013-02-07 |
2014-08-13 |
IP Gesellschaft für Management mbH |
Inhibitors of nedd8-activating enzyme
|
|
US9290475B2
(en)
|
2013-03-14 |
2016-03-22 |
Deuterx, Llc |
3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
|
|
CA2907908A1
(en)
|
2013-04-02 |
2014-10-09 |
Celgene Corporation |
Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
|
|
CA2909160C
(en)
|
2013-04-09 |
2021-05-25 |
Lixte Biotechnology, Inc. |
Formulations of oxabicycloheptanes and oxabicycloheptenes
|
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
|
UA117141C2
(uk)
|
2013-10-08 |
2018-06-25 |
Селджин Корпорейшн |
Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
|
|
WO2015108889A1
(en)
|
2014-01-15 |
2015-07-23 |
Celgene Corporation |
Formulations of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
|
|
AU2015210999A1
(en)
|
2014-01-29 |
2016-07-21 |
Otsuka Pharmaceutical Co., Ltd. |
Device-based risk management of a therapeutic
|
|
EP3160486B1
(en)
|
2014-06-27 |
2020-11-18 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
|
CN106572989B
(zh)
*
|
2014-07-24 |
2021-08-27 |
H·李·莫菲特癌症中心与研究所公司 |
用于治疗骨髓增生异常综合征的蛋白磷酸酶2a抑制剂
|
|
US10034872B2
(en)
|
2014-08-22 |
2018-07-31 |
Celgene Corporation |
Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
|
US10488411B2
(en)
*
|
2015-05-01 |
2019-11-26 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Inflammasome activation in myelodysplastic syndromes
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
EA201890512A1
(ru)
|
2015-08-17 |
2018-09-28 |
Кура Онколоджи, Инк. |
Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
|
|
US9809603B1
(en)
|
2015-08-18 |
2017-11-07 |
Deuterx, Llc |
Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
|
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
|
WO2017214014A1
(en)
|
2016-06-06 |
2017-12-14 |
Celgene Corporation |
Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
|
|
WO2018013689A1
(en)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
|
|
US20180042930A1
(en)
*
|
2016-08-03 |
2018-02-15 |
Celgene Corporation |
Methods of treatment of malignancies
|
|
WO2018107004A1
(en)
|
2016-12-08 |
2018-06-14 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes for modulation of immune response
|
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
EP3565549B1
(en)
|
2017-01-09 |
2022-03-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
US10093647B1
(en)
|
2017-05-26 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
|
|
US10093648B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
|
|
US10093649B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
|
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
|
EP3737376B1
(en)
|
2018-01-09 |
2024-04-17 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human diseases
|
|
KR20210018199A
(ko)
|
2018-03-26 |
2021-02-17 |
씨4 테라퓨틱스, 인코포레이티드 |
이카로스의 분해를 위한 세레블론 결합제
|
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
CN116887844A
(zh)
*
|
2021-01-18 |
2023-10-13 |
活跃生物技术有限公司 |
用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐
|
|
PL4277628T3
(pl)
*
|
2021-01-18 |
2026-02-09 |
Active Biotech Ab |
Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego
|